Insider Transactions in Q2 2022 at Better Therapeutics, Inc. (BTTX)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2022
|
Mark Heinen Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
2,280
+50.0%
|
$2,280
$1.75 P/Share
|
|
Jun 14
2022
|
Andrew J. Armanino |
BUY
Open market or private purchase
|
Indirect |
15,000
+50.0%
|
$15,000
$1.39 P/Share
|
|
Jun 13
2022
|
Geoffrey M. Parker |
BUY
Open market or private purchase
|
Direct |
25,000
+38.46%
|
$25,000
$1.45 P/Share
|
|
Jun 10
2022
|
Mark Heinen Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+20.0%
|
$5,000
$1.56 P/Share
|
|
Jun 09
2022
|
Andrew J. Armanino |
BUY
Open market or private purchase
|
Indirect |
25,000
+14.18%
|
$25,000
$1.65 P/Share
|
|
May 31
2022
|
Kristin Wynholds Chief Product Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,023
+5.02%
|
$5,023
$1.54 P/Share
|
|
May 27
2022
|
Justin Zamirowski Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,677
+4.35%
|
$0
$0.5 P/Share
|
|
May 16
2022
|
Justin Zamirowski Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,236
+50.0%
|
$0
$0.5 P/Share
|